Biophytis SA
ALBPS
Company Profile
Business description
Biophytis SA is a France-based biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging and improve functional outcomes for patients suffering from age-related diseases. Its drug candidate BIO101, is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and DMD.
Contact
BC 9, Batiment A 4eme etage
4 pace Jussieu
Sorbonne University
Paris75005
FRAT: +33 144272300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
24
Stocks News & Analysis
stocks
Here’s how to value a share
Our best resources to help investors determine the value of a share.
stocks
How to avoid dividend disaster
Thinking about common reasons a company might stop paying a dividend can help income investors avoid disappointment.
stocks
GyG punished by market after solid earnings
Although Guzman y Gomez had solid earnings, it failed to meet lofty market expectations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,273.20 | 38.10 | -0.41% |
| CAC 40 | 7,969.69 | 31.40 | 0.40% |
| DAX 40 | 24,363.09 | 69.75 | 0.29% |
| Dow JONES (US) | 45,631.74 | 846.24 | 1.89% |
| FTSE 100 | 9,321.40 | 12.20 | 0.13% |
| HKSE | 25,691.54 | 352.40 | 1.39% |
| NASDAQ | 21,496.54 | 396.22 | 1.88% |
| Nikkei 225 | 42,909.09 | 275.80 | 0.65% |
| NZX 50 Index | 13,128.45 | 85.69 | 0.66% |
| S&P 500 | 6,466.91 | 96.74 | 1.52% |
| S&P/ASX 200 | 9,002.40 | 41.70 | -0.46% |
| SSE Composite Index | 3,848.67 | 22.91 | 0.60% |